Multimedia

Multimedia

Podcasts and video interviews with researchers, commentators, and experts in the field

Big Questions, Tough Answers: Norman “Ned” Sharpless, MD

In more from our interview, Dr. Sharpless shares his vision as National Cancer Institute Director and for overcoming the obstacles to advancing research.

Pulling Back the Curtain: Andra James, MD, MPH

Hear more from our interview with Dr. James, where she shares more about the patients who inspired her to pursue hematology and the importance...
video

Luc-Matthieu Fornecker, MD, PhD: Risks and Benefits of BV + AVD in Treatment-Naive Hodgkin...

In the multicenter BREACH trial, adding brentuximab vedotin to AVD chemotherapy in patients with unfavorable, early-stage Hodgkin lymphoma led to higher rates of PET...
video

Prithviraj Bose, MD: Optimizing Ruxolitinib With Sotatercept for Myelofibrosis

Dr. Bose discusses updated results from a phase II trial of sotatercept alone and with ruxolitinib, the only FDA-approved therapy for myelofibrosis, which also...
video

Jeanette K. Doorduijn, MD, PhD, and Samar Issa, MD: Does Rituximab Improve Survival in...

Results from a randomized phase III trial examining rituximab in patients with central nervous lymphoma show that treatment with rituximab does not improve response...
video

James N. Kochenderfer, MD: Advancing CAR T-Cell Therapy for Myeloma

Dr. Kochenderfer reports "very exciting" results from bb121, a new BCMA-targeting CAR T-cell therapy for treating patients with heavily pretreated myeloma, trending towards less...
video

Yazan F. Madanat, MD: How Does Smoking Increase MDS Risk?

Smoking is associated with an increased risk of developing mutations that lead to myelodysplastic syndromes, but the association changes with patients' smoking patterns. Dr....
video

Stephen J. Schuster, MD: Tisagenlecleucel Promising in Relapsed/Refractory DLBCL

Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma -...
video

Joseph Connors, MD: Bleomycin or Brentuximab Vedotin in Hodgkin Lymphoma?

Replacing bleomycin with brentuximab vedotin in standard ABVD therapy led to a "modest improvement" in outcomes for patients with Hodgkin lymphoma, without increased long-term...
video

Geoffrey L. Uy, MD: Investigating Flotetuzumab in AML and MDS

Dr. Uy discusses preliminary results from a phase I trial of flotetuzumab, a CD123 x CD3 bispecific DART protein, in patients with relapsed/refractory acute...
Advertisement

Current Issue

May 2018, Volume 4, Issue 6

This issue features a look at the hidden costs of importing lower-cost drugs, the optimal hemophilia treatment, the limits of genetic testing, and more.